Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.

Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.

http://www.wikidata.org/entity/Q43115510

about

Arginine deprivation therapy for malignant melanoma Arginine Metabolism in Bacterial Pathogenesis and Cancer Therapy Targeting amino acid metabolism in cancer growth and anti-tumor immune response Arginases and arginine deficiency syndromes Amino acid deprivation using enzymes as a targeted therapy for cancer and viral infections Novel systemic therapy against malignant pleural mesothelioma.Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients.Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells.Arginine deprivation affects glioblastoma cell adhesion, invasiveness and actin cytoskeleton organization by impairment of β-actin arginylation.Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts.Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors.Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase Pegylated arginine deiminase downregulates colitis in murine models.Recombinant human arginase toxicity in mice is reduced by citrulline supplementation Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine.Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy.Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET.Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.In search of druggable targets for GBM amino acid metabolism.De novo engineering of a human cystathionine-γ-lyase for systemic (L)-Methionine depletion cancer therapy.A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma.Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies.Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.Co-application of canavanine and irradiation uncouples anticancer potential of arginine deprivation from citrulline availability A novel and promising therapeutic approach for NSCLC: recombinant human arginase alone or combined with autophagy inhibitor.Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.Targeting methionine auxotrophy in cancer: discovery & exploration.Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights.Treating advanced hepatocellular carcinoma: How to get out of first gear.The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials.Mechanistic studies of agmatine deiminase from multiple bacterial species Drug-induced amino acid deprivation as strategy for cancer therapy.Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.Arginine deiminase: recent advances in discovery, crystal structure, and protein engineering for improved properties as an anti-tumor drug.Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.

P2860

Q24634269-31B9C257-2957-4AD6-9AF2-20FD2F2C7009 Q26765461-24CD4C0F-739A-43F4-9289-BF54C1C7BD9F Q26775425-F2F32ADE-5F00-4A75-8B97-BBC5D944227A Q28396137-01783FDB-B064-4F82-9FC5-C406F72A0D39 Q30040775-55A92DF8-C084-4476-8B49-46EDAD8717D3 Q33890499-3FFF07C7-9467-4680-A3E3-4AD91EA88E13 Q34213639-3284491A-8802-4415-8FA0-A84F2CE97C0D Q34250146-CE53D8B8-00C5-4072-93BF-15D9735FCC88 Q34497105-9CFB0347-EDA1-4E7D-A6B8-082B0D50E6F4 Q34807813-4C4ED7E6-F311-4F33-BEFE-24B9C3EDD1D6 Q35015474-14B889A6-00CA-4C1A-A833-261C11A24486 Q35233239-8F45997A-A229-40BE-A3C5-8EBA0F59469C Q35561304-11E5E73E-7608-4632-BCB6-99891D167393 Q35674875-70DF34C0-156B-4AD0-ACA4-31AAC4AFF025 Q35682009-379B2398-7B00-405B-A7B2-387DC27038F9 Q35725419-33D6A573-5BC2-408B-A40A-DEE0FBB1F66C Q35762225-0A82F54E-DE76-4BD5-8C57-FB54E14573F3 Q35781589-CD5A4363-EE6F-42D3-AB9E-781ECCCCB406 Q35803555-A81AB68F-BA73-4548-B52E-D68DB62F87F9 Q35957293-5B62CC10-70D3-4B09-8AF8-E535CE2A667B Q36121733-25E8931C-37FC-4785-80CF-8205FD093707 Q36293108-283CD13A-2CA2-4EDB-A07A-6E9DD32C6674 Q36405822-92EDF639-8A5E-47AA-8CFA-B7617DAAC50A Q36557480-F5F36DF0-B345-44D7-BE09-05C950D77A97 Q36644408-44D8FBCD-D814-4423-8AD7-052E5FDDEA4B Q36873800-B154A33B-E545-4CE8-964F-E2EB70E9F9E2 Q37465815-1E0C4D0E-574E-4468-9F8C-EE69EF85320E Q37687381-6D293048-B88D-4B5B-B516-7D0EEAD8CCF3 Q37745433-97C6CD88-8545-4070-A135-BA093CEFC124 Q37820202-ED3585BA-96BB-4E81-9F5F-FAAEE06E5CF9 Q37968630-3FB90186-7A37-4D07-9848-73836B579051 Q38181070-64FAAA57-137E-4DE7-99D1-DF51B7A4DF89 Q38201707-5688B7C3-FD10-44FB-A891-7AE5D632EE91 Q38217737-5AD9A6BC-5FCD-4063-9502-9574A4FA3EAD Q38223301-A89694E2-3FD5-4964-A69E-95ADDCF92CE0 Q38466136-90050AE4-C518-420F-8E3A-EC304F4DA3B3 Q38657061-2D70B35A-E247-466E-A349-60840DFD5F90 Q38733577-DCC1185C-A9BA-4495-9B97-7144BD76B02B Q38777479-70077C77-C582-462C-94D9-71E9C163A987 Q38792334-F7FA88F0-5332-4048-A2D7-5ADCAF8BAEB4

P2860

Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.

http://www.wikidata.org/entity/Q43115510

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Phase II study of pegylated ar ...... atic hepatocellular carcinoma.

@en

Phase II study of pegylated ar ...... atic hepatocellular carcinoma.

@nl

type

label

Phase II study of pegylated ar ...... atic hepatocellular carcinoma.

@en

Phase II study of pegylated ar ...... atic hepatocellular carcinoma.

@nl

prefLabel

Phase II study of pegylated ar ...... atic hepatocellular carcinoma.

@en

Phase II study of pegylated ar ...... atic hepatocellular carcinoma.

@nl

P1433

Q43115510-224F9E1A-0B30-4C24-8B8A-63CAE29DBCE6

P1476

Q43115510-98E80EC4-B476-4C46-9994-179302FCAB66

P2093

Q43115510-089F85A9-214B-4BEE-A2BC-700C5CCF67FF

Q43115510-1550528B-553D-431A-85B9-048F46636EF9

Q43115510-4E199F89-78BD-47FD-8969-2B7ACF8016B9

Q43115510-53DD8565-E3B3-400E-8516-BC0FBD1A6ADD

Q43115510-6AD3CB06-116F-4F94-AC6E-2B111ECC6A15

Q43115510-6F3B0EE8-CE7F-4433-BE2B-3AD12FA19982

Q43115510-82F9DD21-5363-48D7-B9B9-C649204478FC

Q43115510-84B017A7-1826-402C-8E23-938FC04C9C82

Q43115510-ABF4F7FF-5312-424E-84EB-1ABA7250BF66

P304

Q43115510-4882E5C2-23A7-4C27-8C05-4CF3C18CEA84

P31

Q43115510-8D0C0A55-CFA2-4C32-ABBC-23AD937C7B5B

P356

Q43115510-903D6A8A-02F1-493D-A895-D191C6F6FF6C

P407

Q43115510-D1357767-3634-41B0-BEAD-7BCA59EDD866

P433

Q43115510-2135C1B0-2279-40ED-85FE-AE81034AF3C6

P478

Q43115510-196A57F5-E8A1-48CA-861A-E56F44A71BD8

P50

Q43115510-6FB3A07B-1B50-4873-8E99-9EA43D15CA58

Q43115510-BE6ED784-E47A-4522-AF5D-AD8F1A958C99

Q43115510-C3503DA4-8A3C-4056-A40F-BAAE08D39232

Q43115510-F0B1C0EF-E255-4357-8880-8B6E7FBE8B8F

P577

Q43115510-E8D9EA58-0FB3-44FD-8E54-96D3ECD1A7CF

P698

Q43115510-312ECC7B-BAD4-4F3D-8B32-6812F1410380

P356

JCO.2009.26.7765

P1433

Journal of Clinical Oncology

P1476

Phase II study of pegylated ar ...... atic hepatocellular carcinoma.

@en

P2093

Angelo A Mastro

http://www.w3.org/2001/XMLSchema#string

Evan S Glazer

http://www.w3.org/2001/XMLSchema#string

Gerardo Beneduce

http://www.w3.org/2001/XMLSchema#string

Mauro Piccirillo

http://www.w3.org/2001/XMLSchema#string

Raffaele Palaia

http://www.w3.org/2001/XMLSchema#string

Raimondo Di Giacomo

http://www.w3.org/2001/XMLSchema#string

Steven A Curley

http://www.w3.org/2001/XMLSchema#string

Vincenzo De Rosa

http://www.w3.org/2001/XMLSchema#string

Vittorio Albino

http://www.w3.org/2001/XMLSchema#string

P304

2220-2226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.26.7765

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Antonella Petrillo

Paolo Antonio Ascierto

Giuseppe Castello

P577

2010-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20351325

http://www.w3.org/2001/XMLSchema#string